Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

Cisplatin is one of the most common drugs used for treatment of solid tumors such as ovarian cancer. Unfortunately, the development of resistance against this cytotoxic agent limits its clinical use. Here we report that YSY01A, a novel proteasome inhibitor, is capable of suppressing survival of cisp...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei, Zhou, Quan, Yuan, Xia, Ge, Ze-mei, Ran, Fu-xiang, Yang, Hua-yu, Qiang, Guang-liang, Li, Run-tao, Cui, Jing-rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911881/
https://www.ncbi.nlm.nih.gov/pubmed/27326257
http://dx.doi.org/10.7150/jca.14519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911881/
https://www.ncbi.nlm.nih.gov/pubmed/27326257
http://dx.doi.org/10.7150/jca.14519

Ejemplares similares